RIZ1 is a histone methyltransferase whose expression and activity are reduced in many cancers. In chronic myelogenous leukemia (CML), blastic transformation is associated with loss of heterozygosity in the region where RIZ1 is located and with decreased RIZ1 expression. Forced RIZ1 expression in model CML blast crisis (BC) cell lines decreases proliferation, increases apoptosis and enhances differentiation. We characterized molecular mechanisms that may contribute to potential CML tumor suppressor properties of RIZ1. Several RIZ1-regulated genes involved in insulin-like growth factor-1 (IGF-1) signaling were identified using cDNA microarrays. RIZ1 was shown to associate with promoter regions of IGF-1 and to increase histone H3 lysine 9 methylation using chromatin immunoprecipitation assays. IGF-1-blocking antibody was used to demonstrate the importance of autocrine IGF-1 signaling in CML-BC cell line viability. Forced RIZ1 expression in CML-BC cell lines decreases IGF-1 receptor activation and activation of downstream signaling components extracellular signal-regulated kinase 1/2 and AKT. These results highlight the therapeutic potential of inhibiting IGF-1 pathway in the acute phase of CML.
Introduction
Chronic myeloid leukemia (CML) is a clonal myeloproliferative disorder characterized by progression from an easily controlled chronic phase to blast crisis (BC), a treatment resistant phase that resembles acute myeloid leukemia or acute lymphoblastic leukemia (Calabretta and Perrotti, 2004) . In CML, evolution to BC is associated with loss of heterozygosity at chromosome region 1p36 (Mori et al., 1998) . RIZ1 is located at 1p36 and frequently undergoes deletion, rearrangements and loss of heterozygosity in a broad spectrum of tumors (Buyse et al., 1995; Muraosa et al., 1996) . RIZ1 expression has been shown to decrease in CML patients during the transformation from chronic phase to BC. Forced RIZ1 expression in CML-BC cell lines decreases proliferation, increases apoptosis and enhances differentiation (Takahashi et al., 2005) . Together these results suggest that RIZ1 may function as a tumor suppressor gene whose inactivation plays an important role in CML-BC transformation.
RIZ1 contains a conserved positive regulatory (PR) domain that methylates histone H3 on lysine 9 (K9) (Kim et al., 2003; Carling et al., 2004) and is important for transcriptional repression (Carling et al., 2004) . RIZ1 also contains an Rb-interacting motif, a nuclear hormone receptor binding motif, an SH3/GTPase domain, eight zinc-finger motifs and a C-terminal PRinteracting domain. These domains and motifs are important for protein interactions (Shapiro et al., 1995; Huang et al., 1998; Carling et al., 2004) , DNA binding (Muraosa et al., 1996; Xie et al., 1997) and estrogen receptor coactivation (Abbondanza et al., 2000; Carling et al., 2004) . RIZ gene produces two proteins, RIZ1 and RIZ2. RIZ2 is identical to RIZ1, except that it is expressed from an internal promoter and produces a protein that lacks the PR domain (Liu et al., 1997) .
RIZ1 expression and activity are reduced in many human cancers by frameshift (Chadwick et al., 2000; Piao et al., 2000) and missense mutations (Steele-Perkins et al., 2001 ) and epigenetic silencing (Du et al., 2001; Chang et al., 2004) . RIZ1À/À mice have a high incidence of diffuse large B-cell lymphoma and a broad spectrum of unusual tumors (Steele-Perkins et al., 2001) . These mice are deficient in RIZ1, but express RIZ2. Therefore, it appears that RIZ1 tumor suppressor activity is localized to its PR domain.
In this study, we characterized mechanisms that would support the role of RIZ1 as a tumor suppressor in CML. We found that RIZ1 regulates genes involved in insulin-like growth factor-1 (IGF-1) signaling and demonstrate that RIZ1 associates with promoter regions of IGF-1 and increases histone H3 K9 methylation. Forced RIZ1 expression in CML-BC cell lines decreases IGF-1 receptor (IGF-1R) phosphorylation and activation of downstream signaling components extracellular signal-regulated kinase (ERK)1/2 and AKT. Blocking autocrine IGF-1 signaling using an IGF-1R-blocking antibody decreases CML-BC cell line viability and suggests that autocrine IGF-1 signaling is important in CML-BC.
Results
Expression of RIZ1 in K562 CML cell line In K562, the RIZ1 promoter is methylated and RIZ1 expression is decreased (Dong et al., 2003) . The low level of RIZ1 expression in K562 provides a model system for analysing the effects of RIZ1 expression in CML-BC. To identify RIZ1-regulated phenotypes and gene targets, K562 was engineered to express RIZ1 (K562 þ RIZ1) from a stably integrated RIZ1 gene. Reverse transcriptase-polymerase chain reaction (RT-PCR) confirmed that K562 and K562 þ RIZ1 both express RIZ2, whereas RIZ1 expression is detected only in K562 þ RIZ1 (Figure 1a ). Western analysis and flow cytometry confirmed RIZ1 protein expression in K562 þ RIZ1 (Figure 1b and c) . Flow cytometry analysis shows that RIZ1 expression in K562 þ RIZ1 is lower than in K562 transiently transfected with a RIZ1 expression plasmid (pRIZ1) and lower than the endogenous RIZ1 levels in human CD34 þ cells. Viabilities of K562, K562 þ RIZ1 and K562 transiently transfected with pRIZ1 were analysed using trypan blue dye exclusion assay (Supplementary Figure 1) . Transient transfection of K562 with pRIZ1 reduced the viability to 14% after 3 days, whereas K562, K562 þ RIZ1 and K562 transfected with pCDNA3 control plasmid have viabilities of 96, 88 and 73%, respectively. The viability of K562 correlates with the level of RIZ1 expression observed in Figure 1c .
Differences in proliferation and apoptosis between K562 and K562 þ RIZ1 were compared using 3-[4,5-dimethylthiazol-2-yl]-2,5-diphenyl tetrazolium bromide (MTT) and annexin V assays. RIZ1 expression decreases proliferation in K562 (Figure 1d ) and increases the number of early apoptotic cells (Figure 1e ). K562 expresses low levels of hemoglobin, reflecting its myeloid/erythroid progenitor phenotype (Hicks et al., 1985) . Benzidine staining was used to monitor whether RIZ1 expression in K562 cells promotes erythroid differentiation. RIZ1 expression increases the number of benzidine-positive K562 cells (Figure 1f ).
Global analysis of RIZ1-induced changes in gene expression in K562 cells RIZ1-regulated genes and pathways were identified using 42 kb complementary DNA (cDNA) microarrays to globally monitor how RIZ1 expression changes the gene expression profile of K562 cells. Genes that are differentially expressed between K562 and K562 þ RIZ1 cells were identified using a combination of significant analysis of microarrays (SAM) (Tusher et al., 2001) and secure digital (SD)-filter analyses (Supplementary Material 1). In total, 19 upregulated and five downregulated genes were identified in the presence of RIZ1 (Table 1) . Several of the up-and downregulated genes were validated using RT-PCR (Supplementary Material 2 and Supplementary Figure 2) . Previously, (G/ C)TTGGC was identified as a RIZ1 binding consensus sequence (Medici et al., 1999) . All RIZ1 downregulated genes and 11/16 RIZ1 upregulated genes contain at least one RIZ1 consensus sequence in the 1 kb region upstream of their start codon (Supplementary Table 1 and Supplementary Material 4).
RIZ1 regulates IGF-1 expression
Western analysis and flow cytometry were used to confirm whether RIZ1 repression of IGF-1 transcription is conserved at the protein level. Consistent with transcription analysis, expression of IGF-1 precursors at 21844 and 16679 Dalton decreases in K562 þ RIZ1 relative to K562 when analysed by Western analysis (Figure 2a) . Similarly, a decrease in IGF-1 expression is observed by flow cytometry (Figure 2b ). The effect of RIZ1 on IGF-1 expression was reversed by transfecting K562 þ RIZ1 with RIZ1 short hairpin RNA (shRNA) ( Supplementary Figure 3a and b) . To establish that RIZ1 repression of IGF-1 expression is not specific to the K562 cell line or the stably transfected RIZ1-expressing cell line (K562 þ RIZ1), K562 and three other CML-BC cell lines (YN-1, ERY-1 and JURL-MK1) were transiently transfected with pRIZ1. All CML-BC cell lines tested showed RIZ1 expression (Supplementary Figure 4) and decreased IGF-1 expression ( Figure 2c ) when transfected with pRIZ1. To verify that decreased intracellular levels of IGF-1 correlate with decreased levels of extracellular IGF-1, we measured IGF-1 levels in the culture medium using enzymelinked immunosorbent assays (ELISAs) (Figure 2d ). Stable expression of RIZ1 in K562 and transient expression of pRIZ1 in K562 and YN-1 decreased extracellular levels of IGF-1.
RIZ1 binds to IGF-1 promoter and enhances histone H3 lysine 9 methylation Chromatin immunoprecipitation (ChIP) assays were used to determine whether RIZ proteins associate with IGF-1 promoter 1 (PR1) and IGF-1 growth hormone response element (GHRE) (Woelfle et al., 2003) (Figure  3a and b). To assay RIZ2 binding, ChIP assays were performed in K562, which expresses mainly RIZ2, using an antibody (panRIZ) that recognizes RIZ1 and RIZ2. In K562, RIZ2 associates primarily with the IGF-1 PR1 promoter and has an approximately 50-fold decrease in association with GHRE. Expression of RIZ1 in K562 (K562 þ RIZ1) increases the amount of RIZ protein that associates with PR1 (2.8-fold increase) and GHRE (21-fold increase), indicating that RIZ1 associates with both IGF-1 promoter regions. In K562 and K562 þ RIZ1, RIZ proteins associate stronger with PR1 than GHRE.
RIZ1-specific antibody was used to compare the binding of RIZ1 to IGF-1 PR1 and GHRE ( Figure 3b ). In K562, which expresses very low levels of RIZ1, RIZ1 associates weakly with IGF-1 PR1 and GHRE. In K562 þ RIZ1, RIZ1 association with IGF-1 PR1 and GHRE increases by 3.6-fold and 4.5-fold, respectively. RIZ1 associates with similar strength to PR1 and GHRE. The strength of IGF-1 promoter association detected using RIZ1 antibody is lower at PR1 and similar at GHRE relative to IGF-1 promoter association detected using panRIZ antibody. Stronger association at PR1 detected with the panRIZ antibody combined with the increase in association at PR1 and GHRE in K562 þ RIZ1 detected with panRIZ and RIZ1 antibodies, suggests a model whereby RIZ2 associates more strongly with PR1 than with GHRE, whereas RIZ1 associates with both PR1 and GHRE, but its association at PR1 is less than RIZ2. RIZ1 and RIZ2 differ by the presence of a PR domain; therefore, specific interaction of RIZ1 with the IGF-1 GHRE is most likely mediated through a PR domain protein interaction with a bridging protein. The PR domain has been shown 
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E Pastural et al previously to function as a protein-binding interface (Huang et al., 1998) . RIZ1 contains a PR domain that has histone H3 K9 methylation activity. To determine whether this activity alters histone H3 K9 methylation status of IGF-1 PR1 and GHRE, ChIP assays were performed using antidimethyl-histone H3 K9 antibody. Expression of RIZ1 (K562 þ RIZ1) increased the methylation of histone H3 K9 at IGF-1 PR1 (1.7-fold) and GHRE (threefold) relative to K562 (Figure 3b ). PR1 promoter is more heavily methylated at histone H3 K9 relative to GHRE. These results suggest that expression of RIZ1 decreases IGF-1 expression by enhancing histone H3 K9 methylation. To ensure that changes in histone H3 K9 methylation are not due to changes in nucleosome density, ChIP assays were performed using anti-H3 antibody. No significant changes in histone H3 levels were observed at PR1 or GHRE in K562 and K562 þ RIZ1, indicating that changes in histone H3 K9 methylation are not due to nucleosome depletion.
RIZ1 regulates IGF-1 signaling
The ability of RIZ1 to repress IGF-1 expression should also inhibit the activation of the IGF-1R. No differences in IGF-1R expression between K562 and K562 þ RIZ1 were observed by cDNA microarray and this was confirmed by RT-PCR (Supplementary Figure 5) and Western analysis (Figure 4a ). IGF-1R activation was monitored by characterizing its autophosphorylation upon IGF-1 binding. In K562 þ RIZ1, immunoprecipitated IGF-1R showed reduced IGF-1R phosphorylation relative to K562 (Figure 4a) . Expression of RIZ1 in K562 cells also reduced the activity of AKT1 and ERK1/2 (Figure 4b and c) , which are downstream signaling molecules of the IGF1-R. To confirm whether IGF-1 signaling affects CML-BC cell line viability, an anti-IGF-1R-blocking antibody was used to block IGF-1R activation by autocrine IGF-1. The percentage of viable cells relative to cells treated with immunoglobulin G (IgG) control decreased in K562, JURL-MK1, ERY-1 and YN-1 cell lines treated with IGF-1R-blocking antibody (Figure 4d ).
Discussion
Currently, the molecular mechanisms responsible for driving the transition of CML from chronic phase to BC 
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are not well characterized. In CML, the evolution to BC is associated with loss of heterozygosity in the region of 1p36 where RIZ1 is located (Mori et al., 1998) . Analysis of matched patient material from chronic phase and BC shows that RIZ1 expression is decreased in BC. A possible mechanism for decreased RIZ1 expression in CML-BC is promoter hypermethylation. In K562, the RIZ1 promoter is hypermethylated and addition of a methylation inhibitor, 5-aza-2 0 -deoxycytidine, results in RIZ1 expression (Dong et al., 2003) . Epigenetic silencing has also been reported to reduce RIZ1 expression in a variety of other cancers (Du et al., 2001; Chang et al., 2004) . Forced RIZ1 expression in CML-BC cell lines decreases proliferation, increases apoptosis and enhances differentiation (Takahashi et al., 2005) . Existing evidence supports a role for RIZ1 as a candidate tumor suppressor gene whose inactivation may play an important role in CML disease progression.
Typically, secondary chromosome or molecular aberrations that lead to CML-BC cause growth factorindependent proliferation and survival, and a dramatic arrest in differentiation (Calabretta and Perrotti, 2004) . To understand molecular mechanisms behind RIZ1-induced reduction in cell proliferation and enhancement in apoptosis and differentiation, genes and pathways regulated by RIZ1 in K562 were analysed using cDNA microarrays. Twenty-four RIZ1-regulated genes were discovered that are involved in a variety of biological processes with a subgroup of genes involved in IGF-1 signaling.
IGF-1 is reported to augment proliferation of human erythroid progenitor cells (Woessmann et al., 2004) and to stimulate the growth of myeloid and lymphoid progenitors (Pepe et al., 1987) . RIZ1 downregulates IGF-1 expression and upregulates insulin-like growth factor-binding protein 2 (IGFBP2) and SPARC expression. IGFBP2 is proposed to bind and sequester IGF-1, which causes growth inhibition (Hoeflich et al., 2001) . SPARC regulates IGF-1 signaling in mesangial cells by repressing ERK1/2 pathway and expression of IGF-1, 
IGF-2 and IGF-1R (Francki et al., 2003) . RIZ1 also reduces phosphorylation of the IGF-1R and the activity of AKT and ERK1/2 pathways. In K562, ERK1/2 has been shown to play a role in proliferation, apoptosis and erythroid differentiation (Woessmann and Mivechi, 2001) , whereas AKT1 only affects proliferation and apoptosis (Kang et al., 1999) . Deregulation of RIZ1 expression and activity may promote CML-BC phenotypes by controlling autocrine IGF-1 production and blocking IGF-1 signaling pathways. RIZ1 regulates transcription by binding DNA elements. It functions as a weak activator of transcription when it is bound to the multiple tissue expression (MTE) DNA element of the human-oxygenase-1 gene (Muraosa et al., 1996) . RIZ1 represses herpes simplex virus hymidine kinase and simian virus 40 early promoters, which are primarily controlled by GC-rich Sp-1 sites (Xie et al., 1997) . GC-rich regions are common in many promoters suggesting that RIZ1 controls a large number of genes. Surprisingly, only 24 genes were observed whose expression is significantly regulated by RIZ1, suggesting that RIZ1 is not a universal regulator of transcription. Previously, Medici et al. (1999) characterized RIZ1 as a DNA-binding protein that cooperates RIZ1 has in vitro histone H3 K9 methylation activity (Kim et al., 2003) and is a weak activator (Muraosa et al., 1996) and a repressor (Xie et al., 1997) of transcription. Carling et al. (2004) showed that RIZ1 interacts directly and indirectly with the pS2 gene promoter in MCF7 breast cancer cells in the absence or presence of estrogen, respectively. When RIZ1 is bound directly to the pS2 promoter, it increases the methylation of histone H3 K9. When estrogen is added to MCF7 cells, RIZ1 binding to pS2 promoter is reduced and methylation of histone H3 K9 decreases with a concurrent increase in acetylation. Gazzerro et al. (2006) also showed that RIZ1 interacts with the c-Myc promoter in MCF7 cells. Decrease in RIZ1 expression caused an increase in c-Myc expression with a concurrent increase in histone H3 acetylation. ChIP assays using a RIZ1 antibody in K562 þ RIZ1 demonstrate that RIZ1 interacts with IGF-1 PR1 and GHRE. ChIP assays using panRIZ antibody in K562, which expresses RIZ2 and very low levels of RIZ1, indirectly show that RIZ2 interacts much more strongly with PR1. These results are surprising as both RIZ1 and RIZ2 contain the same DNA-binding domains. It is possible that the PR domain of RIZ1 is interacting indirectly through a protein interaction with the IGF-1 GHRE. RIZ1 binding to IGF-1 PR1 and GHRE increases methylation of histone H3 K9 and represses IGF-1 expression. Both Carling et al. (2004) and our results support a model whereby direct or indirect binding of RIZ1 to promoters can inhibit gene expression by increasing the methylation of histone H3 K9.
In summary, we propose a model where in chronic phase CML there is an expansion of breakpoint cluster region-Abelson-positive CML progenitor cells that maintain the ability to undergo apoptosis and differentiation. Epigenetic or genetic aberrations in RIZ1 expression and activity result in an increase in IGF-1 signaling and a blockage of the apoptotic and differentiation pathways, which leads to an expansion of the CML blast cell population. This model highlights RIZ1 and IGF-1 signaling pathways as potential therapeutic targets for treating CML-BC.
Materials and methods
Supplementary Material Section contains a detailed list of reagents, antibodies and methods. RIZ1-regulated genes and pathways E Pastural et al (Ribadeau Dumas et al., 2004) and JURL-MK1 is from DSMZ (Braunschweig, Germany (ACC 532)). Culture media and construction details for K562 þ RIZ1 are described in Supplementary Methods. CD34 þ cells were purified from granulocyte colony-stimulating factor-mobilized peripheral blood using a Direct CD34 Progenitor Cell Isolation Kit from Miltenyi Biotech (Bergisch Gladbach, Germany). The Nucleofector system (Amaxa Inc., Cologne, Germany) was used for transfecting plasmid into cell lines.
Microarray analysis cDNA was prepared and hybridizations were performed according to guidelines provided by the University Health Network/Ontario Cancer Institute (Toronto, ON, Canada). The microarrays were washed according to the Stanford Microarray Facility procedure (Stanford, CA, USA). cDNA microarrays were scanned using an Axon Instruments GenePix 4000B scanner. Images were analysed using GenePix Pro V. 4.1 (Molecular Devices, Union City, CA, USA). Acuity 3.1 (Molecular Devices) was used for normalization, gene filtering and gene annotation. SAM (Tusher et al., 2001) and SD-filter analyses were used to determine whether genes were differentially expressed in K562 and K562 þ RIZ1.
Chromatin immunoprecipitation
ChIP assays were performed using the chromatin immunoprecipitation assay kit from Upstate (Charlottesville, VA, USA).
Flow cytometry IGF-1 and RIZ1 were analysed by indirect immunofluorescence in fixed, permeabilized cells using an Epics XL (Beckman Coulter, Mississauga, ON, Canada) flow cytometer.
shRNA experiments A RIZ1 shRNA expression plasmid (pRIZ1shRNA) from OPEN Biosystems (Huntsville, AL, USA) was transfected into cell lines using Nucleofector technology (Amaxa Inc.). A shRNA non-silencing control vector (pshRNAcon) was used as a negative control (OPEN Biosystems).
Cell viability, proliferation, apoptosis and differentiation assays Cell viability was determined using trypan blue dye exclusion. Cell proliferation was measured using MTT assays as described previously (van de Loosdrecht et al., 1994) . Apoptotic cells were detected using the annexin V-FITC Apoptosis Detection Kit (BD Biosciences, Mississauga, ON, Canada). Cells containing heme or hemoglobin were detected using benzidine/hydrogen peroxide solution as described (Rutherford et al., 1979) .
IGF-1 ELISA IGF-1 concentrations were determined using a quantitative enzyme immunoassay (ELISA) technique (Quantikine Human IGF-1 Immunoassay, R&D Systems, Minneapolis, MN, USA).
IGF-1-blocking assay IGF-1R-blocking antibody experiments were performed similar to Aro et al. (2002) .
